Comparative Pharmacology
Head-to-head clinical analysis: ADVIL versus CHILDREN S IBUPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL versus CHILDREN S IBUPROFEN.
ADVIL vs CHILDREN'S IBUPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby reducing pain, fever, and inflammation.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day (OTC). For prescription: 400-800 mg orally 3-4 times daily; maximum 3200 mg/day.
Oral: 200-400 mg every 6-8 hours as needed; maximum daily dose: 1200 mg (OTC) or 3200 mg (prescription).
None Documented
None Documented
2-4 hours (terminal elimination half-life in adults; prolonged in overdose or renal impairment: up to 8-12 hours)
2-4 hours (terminal elimination half-life in children; may be prolonged in neonates or hepatic impairment)
Renal: ~95% (hepatic metabolites and conjugates, <1% unchanged); biliary/fecal: ~5%
Renal: 90% (primarily as conjugated metabolites, <10% unchanged); biliary/fecal: minor
Category C
Category D/X
NSAID
NSAID